KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Other financing activities (2016 - 2025)

Historic Other financing activities for Gsk (GSK) over the last 17 years, with Q4 2025 value amounting to -$33.3 million.

  • Gsk's Other financing activities fell 13198.32% to -$33.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $62.9 million, marking a year-over-year decrease of 6160.02%. This contributed to the annual value of $60.7 million for FY2025, which is 6321.25% down from last year.
  • According to the latest figures from Q4 2025, Gsk's Other financing activities is -$33.3 million, which was down 13198.32% from -$64.8 million recorded in Q3 2025.
  • Gsk's Other financing activities' 5-year high stood at $12.4 billion during Q1 2022, with a 5-year trough of -$253.7 million in Q3 2021.
  • Moreover, its 5-year median value for Other financing activities was $9.9 million (2021), whereas its average is $1.2 billion.
  • As far as peak fluctuations go, Gsk's Other financing activities skyrocketed by 11281645.0% in 2022, and later tumbled by 72297.28% in 2025.
  • Over the past 5 years, Gsk's Other financing activities (Quarter) stood at $9.4 million in 2021, then skyrocketed by 112816.45% to $10.7 billion in 2022, then tumbled by 97.86% to $228.4 million in 2023, then plummeted by 54.48% to $104.0 million in 2024, then tumbled by 131.98% to -$33.3 million in 2025.
  • Its last three reported values are -$33.3 million in Q4 2025, -$64.8 million for Q3 2025, and $197.4 million during Q2 2025.